Transient Premature Ovarian Insufficiency Post-COVID-19 Infection

Anti-ovarian antibodies (AOAs) have been linked to autoimmune premature ovarian insufficiency (POI). This report details a case in which a patient experienced transient POI after a COVID-19 infection and tested positive for AOA. After treatment with oral contraceptives and subsequent high-dose oral...

Descripción completa

Detalles Bibliográficos
Autores principales: Gorman, Colleen N, Abdalla, Tori E, Sultan, Yasmina, Grabois, Spencer A, Wood, Ellen G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Obstetrics/Gynecology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171879/
https://www.ncbi.nlm.nih.gov/pubmed/37182044
http://dx.doi.org/10.7759/cureus.37379
Descripción
Sumario:Anti-ovarian antibodies (AOAs) have been linked to autoimmune premature ovarian insufficiency (POI). This report details a case in which a patient experienced transient POI after a COVID-19 infection and tested positive for AOA. After treatment with oral contraceptives and subsequent high-dose oral corticosteroids, the patient underwent fertility treatment with in vitro fertilization (IVF). A total of 23 oocytes were retrieved. Two euploid blastocysts and three untested blastocysts were successfully created. This report hypothesizes the connection between autoimmune POI, AOA, and COVID-19. Conflicting data have been reported linking COVID-19 and ovarian injury. However, it is suggested that COVID-19 transiently impacts the menstrual cycle and anti-Mullerian hormone (AMH) levels. Treatment to overcome poor ovarian response due to AOA has not been adequately determined; however, similar autoimmune conditions have been successfully treated with corticosteroids.

Ejemplares similares